Gilead relinquishes orphan drug designation for potential COVID-19 treatment
Gilead Sciences has asked the US Food and Drug Administration to rescind an orphan drug designation for its experimental covid-19 treatment just days after the agency granted the status.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10